RepliCel Life Sciences Inc.

REPCF

CA76027P4006

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 08:50:42 15/03/2024 pm IST			5-day change	1st Jan Change
0.0428 ^USD	+4.99%		-.--%	-4.89%

31/05	RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/05	RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Geoff MacKay Joins RepliCel Life Sciences Inc.'s Board of Directors

October 15, 2015 at 05:30 pm IST

RepliCel Life Sciences Inc. announced the appointment of Mr. Geoff MacKay as an independent director of the firm, effective from October 14, 2015. MacKay is currently CEO of AVROBIO Inc.

Latest news about RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	31/05	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/05	CI
RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18/04	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/23/24	CI
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	31/23/31	CI
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17/23/17	CI
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17/23/17	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/23/31	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02	CI
RepliCel Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	01/23/01	CI
RepliCel Life Sciences Inc. announced that it has received CAD 1.0131 million in funding	14/23/14	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.01225 million in funding	08/23/08	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.01225 million in funding	02/23/02	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.05 million in funding	26/23/26	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.116419 million in funding	26/23/26	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.116419 million in funding	17/23/17	CI
RepliCel Life Sciences Inc. announced that it has received $0.558837 million in funding	06/23/06	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.841965 million in funding	03/23/03	CI
RepliCel Life Sciences Inc. announced that it expects to receive $0.558837 million in funding	30/22/30	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	30/22/30	CI
RepliCel Life Sciences Inc. Announces Executive Changes	28/22/28	CI
RepliCel Life Sciences Inc. Announces Executive Changes	28/22/28	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.8 million in funding	06/22/06	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	30/22/30	CI

Chart RepliCel Life Sciences Inc.

Duration

Period

More charts

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Companyâs cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REPLICEL LIFE SCIENCES INC.	-4.89%	2.78M
VERTEX PHARMACEUTICALS INCORPORATED	+16.38%	122B
REGENERON PHARMACEUTICALS, INC.	+21.33%	116B
ARGENX SE	+22.18%	27.03B
BIONTECH SE	-21.20%	20.36B
GENMAB A/S	-16.89%	16.43B
BEIGENE, LTD.	-18.01%	15.91B
WUXI APPTEC CO., LTD.	-44.74%	15.6B
SAREPTA THERAPEUTICS, INC.	+61.20%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+3.35%	13.59B